Long-term effects of cabergoline and Levodopa in Japanese patients with early Parkinson's disease: A 5-year prospective study

Hiroya Utsumi, Makoto Iwata, Naohito Yamaguchi, Yoshihide Sunada, Fumihiko Sakai, Norihiro Suzuki, Nobuo Araki, Imaharu Nakano, Mitsuru Kawamura, Teruo Shimizu, Yukito Shinohara, Hiroya Utsumi, Koichi Hirata, Yasuo Katayama, Tomohiko Mizutani, Akihiko Uchiyama, Toru Mannen, M. Iwata, N. Yamaguchi, Shiori HashimotoMasahisa Kodama, Yuko Shimizu, Tatsufumi Murakami, Yutaka Ohsawa, Takahiro Iizuka, Kazushi Takahashi, Shigeru Nogawa, Hidetada Takeda, Takahiro Amano, Toshimasa Yamamoto, Kunio Shimazu, Mitsuya Morita, Ken Ichi Fujimoto, Hidetomo Murakami, Yukihiro Hasegawa, Fumihito Yoshii, Hirohide Takahashi, Hiroo Terashi, Takahide Nagashima, Kunihiko Sakurai, Yoshiaki Kaji, Toshiyuki Kawakami, Norito Kokubun, Yasutoshi Daimon, Hitoshi Kubo, Tetsuya Ishihara, Hiroshi Nagayama, Makoto Hamamoto, Satoshi Kamei, Yutaka Suzuki, Masahiro Sonno

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Several international studies have suggested that treatment of early Parkinsons disease (PD) with a dopamine agonist instead of levodopa delays the occurrence of motor complications. This 5-year prospective, open, multicenter randomized study aimed to compare the effects of cabergoline on the onset of motor complications with those of levodopa in Japanese patients with early PD. Patients who had never been treated with dopamine agonists or levodopa were enrolled in this study. Four of 45 patients in the cabergoline group and 11 of 46 patients in the levodopa group developed motor complications. The estimated cumulative incidence of motor complications in the cabergoline and levodopa groups was 17% and 34% (hazard ratio, 0.57; 95% confidence interval, 0.18-1.81; p = 0.347). Thirty-five adverse events (AEs) were reported in 24 patients in the cabergoline group, while 16 AEs were reported in 13 patients in the levodopa group. Patients in the cabergoline group showed fewer motor complications than did those in the levodopa group, although the difference was not statistically significant. However, the hazard ratio found in this study was similar to those in previous reports.

Original languageEnglish
Pages (from-to)163-170
Number of pages8
JournalActa Medica Okayama
Volume66
Issue number2
Publication statusPublished - 2012

Keywords

  • Cabergoline
  • Levodopa
  • Motor complications
  • Parkinson's disease

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Long-term effects of cabergoline and Levodopa in Japanese patients with early Parkinson's disease: A 5-year prospective study'. Together they form a unique fingerprint.

Cite this